Drug interaction potential with inhibitors of HIV protease

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 774-778

  Van Cleef, Gwendolyn F ^a   Fisher, Evelyn J ^a   Polk, Ron E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; DAPSONE; DESIPRAMINE; DICLOFENAC; DIDANOSINE; ETHINYLESTRADIOL; FLUCONAZOLE; HALOPERIDOL; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LORATADINE; METRONIDAZOLE; NELFINAVIR; NIFEDIPINE; OMEPRAZOLE; PAROXETINE; RIFABUTIN; RITONAVIR; SAQUINAVIR; TEMAZEPAM; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PROTEINASE INHIBITION; UVEITIS; VIRUS INHIBITION;

CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR;

EID: 0030756282     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995;8(2):200-39.
2. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086-8.
3. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996;51(5):701-12.
4. Anonymous. Merck Crixivan temporary distribution to begin filling scripts March 25 through independent pharmacy service; scale-up facilities to be ready in six months. FDC Rep 1996:58;3-4.
5. Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-14.
6. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
7. Roche Laboratories. Invirase (saquinavir) package insert. Nutley, NJ; 1995 December.
8. Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago, IL; 1996 February.
9. Merck & Co., Inc. Crixivan (indinavir) package insert. West Point, PA; 1996 March.
10. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
11. Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994;48:2147-56.
12. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995.
13. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995.
14. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
15. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
16. De Wit S, Turner D, Debier M, et al. Absence of interaction between indinavir and fluconazole; a pharmacokinetic study in HIV patients. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
17. McCrea J, Woolf E, Sterrett A, et al. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Presented at the annual meeting of the American Association of Pharmaceutical Scientists, Seattle, Washington, October 28-31, 1996.
18. Winchell DA, McCrea JB, Tomasko L, et al. Study of potential pharmacokinetic interaction between indinavir and clarithromycin. Presented at the annual meeting of the American Association of Pharmaceutical Scientists, Seattle, Washington, October 28-31, 1996.
19. Outlet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin [abstr]. Clin Pharmacol Ther 1996;59(2):143.
20. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
21. Oullet D, Hsu A, Quian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
22. Cato A, Cavanaugh JH, Shi H, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
23. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
24. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
25. Cato A, Qian J, Carothers L, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine [abstr]. Clin Pharmacol Ther 1996;59(2):143.
26. The Indinavir Pharmacokinetic Study Group. Indinavir drug interaction studies. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
27. Wlodawer A. Rational drug design: the proteinase inhibitors. Pharmacotherapy 1994;14(6 pt 2):9S-20.
28. Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV positive patients initiated on protease inhibitors. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
29. Everson RE, Weidle PJ, Perdue BE, et al. Evaluation of drug interactions with indinavir. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
30. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124(12):1039-50.
31. Sun E, Heath-Chiozzi M, Cameron W, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
32. Havlur DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335(6):392-8.
33. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335(6):384-91.